NASDAQ: THARTharimmune Inc Stock
$3.99+0.75 (+23.15%)
Updated Nov 5, 2025
THAR Price
$3.99
Fair Value Price
$2.75
Market Cap
$18.49M
52 Week Low
$0.95
52 Week High
$9.08
P/E
-0.65x
P/B
50.34x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$12.01M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
5.89
Operating Cash Flow
-$10M
Beta
0.72
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
THAR Overview
Hillstream BioPharma, Inc., a pre-clinical biotechnology company, develops novel therapies for treatment resistant cancers. Its approach targets ferroptosis, an anti-cancer mechanism resulting in iron-mediated cancer cell death. Hillstream BioPharma was incorporated in 2017 and is based in Bridgewater, NJ.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine THAR's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
THAR
Ranked#218 of 488
Ranked#218 of 488
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $105.70 | A | |
| $7.96 | A | |
| $7.17 | A |
Be the first to know about important THAR news, forecast changes, insider trades & much more!
THAR News
Overview
Due Diligence Score
–
Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how THAR scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
THAR ($3.99) is overvalued by 45.31% relative to our estimate of its Fair Value price of $2.75 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
THAR ($3.99) is not significantly undervalued (45.31%) relative to our estimate of its Fair Value price of $2.75 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
THAR is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more THAR due diligence checks available for Premium users.
Valuation
THAR fair value
Fair Value of THAR stock based on Discounted Cash Flow (DCF)
Price
$3.99
Fair Value
$2.75
Overvalued by
45.31%
THAR ($3.99) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
THAR ($3.99) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
THAR is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
THAR price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.65x
Industry
-18.37x
Market
40.58x
THAR price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
50.34x
Industry
4.9x
THAR is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
THAR's financial health
Profit margin
Revenue
$0.0
Net Income
-$1.9M
Profit Margin
0%
THAR's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$2.5M
Liabilities
$2.2M
Debt to equity
5.89
THAR's short-term assets ($2.53M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
THAR's short-term assets ($2.53M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
THAR's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$1.1M
Investing
$0.0
Financing
$2.3M
THAR's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
THAR vs Biotech Stocks
Tharimmune Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.